Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
RVMD 
Revolution Medicines Inc (RVMD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/10/2025: RVMD (4-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $72.91
1 Year Target Price $72.91
| 8 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 91.32% | Avg. Invested days 89 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 07/10/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 7.17B USD | Price to earnings Ratio - | 1Y Target Price 72.91 |
Price to earnings Ratio - | 1Y Target Price 72.91 | ||
Volume (30-day avg) 12 | Beta 1.1 | 52 Weeks Range 29.17 - 62.40 | Updated Date 07/11/2025 |
52 Weeks Range 29.17 - 62.40 | Updated Date 07/11/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.01 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -23.09% | Return on Equity (TTM) -36.68% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 5206692794 | Price to Sales(TTM) 9035.1 |
Enterprise Value 5206692794 | Price to Sales(TTM) 9035.1 | ||
Enterprise Value to Revenue 8370.02 | Enterprise Value to EBITDA -9.71 | Shares Outstanding 186268000 | Shares Floating 168192142 |
Shares Outstanding 186268000 | Shares Floating 168192142 | ||
Percent Insiders 1.99 | Percent Institutions 105.97 |
Upturn AI SWOT
Revolution Medicines Inc
Company Overview
History and Background
Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit frontier targets that drive intrinsic drug resistance and cancer growth. Founded in 2014, the company has built a robust pipeline of RAS(ON) inhibitors. Revolution Medicines went public in February 2020.
Core Business Areas
- RAS(ON) Inhibitors: Focuses on developing inhibitors of RAS proteins in their active (GTP-bound) state, a novel approach to targeting cancers driven by RAS mutations.
Leadership and Structure
Mark A. Goldsmith, M.D., Ph.D. (CEO). The company has a board of directors and is structured with research, development, clinical, and administrative departments.
Top Products and Market Share
Key Offerings
- RMC-6236 (RAS(ON) Inhibitor): RMC-6236 is an oral RAS(ON) inhibitor targeting multiple KRAS variants. Currently in clinical trials. Competitors include Mirati Therapeutics (MRTX), Amgen (AMGN), and other companies developing RAS inhibitors.
- RMC-9805 (KRAS G12C(ON) Inhibitor): RMC-9805 is a potent and selective KRAS G12C(ON) inhibitor designed to only interact with the protein when bound to GTP. Currently in clinical trials. Potential competitors: Mirati Therapeutics (MRTX), Amgen (AMGN).
Market Dynamics
Industry Overview
The oncology drug market is a large and rapidly growing market, driven by increasing cancer incidence, advances in cancer biology, and the development of new targeted therapies. The market is highly competitive, with numerous pharmaceutical and biotechnology companies developing and marketing cancer drugs.
Positioning
Revolution Medicines is positioned as a leader in the development of RAS(ON) inhibitors, a novel approach to targeting RAS-driven cancers. Their competitive advantage lies in their unique technology platform and expertise in RAS biology.
Total Addressable Market (TAM)
The TAM for RAS-targeted therapies is estimated to be in the billions of dollars. Revolution Medicines is positioned to capture a significant share of this market with its pipeline of RAS(ON) inhibitors.
Upturn SWOT Analysis
Strengths
- Novel RAS(ON) inhibitor technology platform
- Strong scientific expertise in RAS biology
- Robust pipeline of RAS(ON) inhibitors
- Experienced management team
- Strong financial position
Weaknesses
- Clinical-stage company with no currently marketed products
- High development risk associated with novel therapies
- Reliance on successful clinical trial outcomes
- Competition from established pharmaceutical companies
Opportunities
- Expansion of RAS(ON) inhibitor pipeline
- Partnerships with pharmaceutical companies
- Successful clinical trial results
- Regulatory approvals
- Expansion into new cancer indications
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from other RAS inhibitors
- Patent challenges
- Economic downturn
Competitors and Market Share
Key Competitors
- MRTX
- AMGN
- DGX
Competitive Landscape
Revolution Medicines has an advantage in the RAS(ON) inhibitor space. The disadvantage includes being a small company versus AMGN. MRTX is more advanced with KRAS G12C inhibitors.
Growth Trajectory and Initiatives
Historical Growth: Revolution Medicines' growth is tied to its clinical program advancements and financial investments.
Future Projections: Future projections depend on the successful advancement of its pipeline and can be obtained from analyst reports.
Recent Initiatives: Revolution Medicines has recently focused on advancing its clinical programs for RMC-6236 and RMC-9805.
Summary
Revolution Medicines is a clinical-stage company with a novel technology platform targeting RAS-driven cancers. Its pipeline of RAS(ON) inhibitors shows promise. Its main challenge is clinical development and competition. The company has a strong scientific team but faces execution risks.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Revolution Medicines Investor Relations, SEC Filings, Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market data and financial figures are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Revolution Medicines Inc
Exchange NASDAQ | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2020-02-13 | CEO, President & Chairman Dr. Mark A. Goldsmith Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 616 | Website https://www.revmed.com |
Full time employees 616 | Website https://www.revmed.com | ||
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; RMC-5552, a selective inhibitor of mTORC1 signaling in tumors, which is in phase 1 clinical trial; and RMC-5845 that targets SOS1. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.